Recommendations For Reporting Pharmacoeconomic Evaluations Important To Egypt

Published Oct 8, 2013
Cairo, Egypt – The introduction of economic evaluations for pharmaceuticals or health technologies can help to optimize outcomes from resources allocations. Researchers from the Egyptian Ministry of Health and Population proposed recommendations for reporting pharmacoeconomic evaluations, taking into account current practices and capacities for conducting pharmacoeconomic evaluations in Egypt. A focus group of decision makers provide recommendations for researchers in presenting pharmacoeconomic evaluations in Egypt with special focus on pricing and/or reimbursement applications of pharmaceuticals. As an initial step, the Egyptian Ministry of Health and Population was encouraged to establish a pharmacoeconomic unit for the support of pricing and reimbursement decisions. Recommendations for pharmacoeconomic evaluations will provide an essential tool for the support of a transparent and uniform process in evaluation of the clinical benefit and costs of drugs that do not rely on the use of low acquisition cost as the primary basis for selection. Gihan Elsisi, MSc, Central Administration for Pharmaceutical Affairs and lead author of the study says, "Recommendations for reporting economic evaluations will help inform health care decisions for improving health care systems and achieve better health for the Egyptian population." The full study, “Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt” is published in Value in Health Regional Issues.
Value in Health Regional Issues  (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Related Stories

Value in Health Regional Issues Expands Editorial Scope and Reveals Plans to Transition to Gold Open Access Model

Jan 23, 2024

Value in Health Regional Issues, an official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the expansion of its editorial scope and its plan to transition to a gold open access journal.

Empowering Change: Transforming Health Systems in Low- and Middle-Income Countries

Jan 22, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that highlight innovative approaches to improving health outcomes in low- and middle-income countries through partnerships between health economics researchers and policy makers.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×